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The retinal vascular system is the only part of the human body available for direct, in vivo inspection. Noninvasive retinal markers
are important to identity patients in risk of sight-threatening diabetic retinopathy. Studies have correlated structural features like
retinal vascular caliber and fractals with micro- and macrovascular dysfunction in diabetes. Likewise, the retinal metabolism can
be evaluated by retinal oximetry, and higher retinal venular oxygen saturation has been demonstrated in patients with diabetic
retinopathy. So far, most studies have been cross-sectional, but these can only disclose associations and are not able to separate
cause from eﬀect or to establish the predictive value of retinal vascular dysfunction with respect to long-term complications.
Likewise, retinal markers have not been investigated as markers of treatment outcome in patients with proliferative diabetic
retinopathy and diabetic macular edema. The Department of Ophthalmology at Odense University Hospital, Denmark, has a
strong tradition of studying the retinal microvasculature in diabetic retinopathy. In the present paper, we demonstrate the
importance of the retinal vasculature not only as predictors of long-term microvasculopathy but also as markers of treatment
outcome in sight-threatening diabetic retinopathy in well-established population-based cohorts of patients with diabetes.
1. Introduction
Diabetic retinopathy (DR) is the leading cause of blindness in
the working-age population around the world [1, 2]. Given
that diabetes is a global epidemic, we expect an increasing
burden on the ophthalmological health care system for the
upcoming years. Pivotal studies like the Diabetes Control
and Complication Trial (DCCT) have demonstrated the
beneﬁcial eﬀect of strict glycemic control in order to prevent
or at least delay DR [3]. Nevertheless, the study also revealed
that the combined eﬀect of diabetes duration and glycemic
regulation was only able to explain 11% of the total variation
in the risk of DR, which leaves 89% for other reasons and
mechanisms [4]. In addition, it took more than two years of
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strict glycemic control to demonstrate a beneﬁcial eﬀect on
DR incidence and DR progression [3]. Hence, it is important
to identify other mechanisms and early noninvasive markers
of disease activity in order to stratify screening and treatment
regimen for patients with DR.
The aim of this paper was to demonstrate noninva-
sive structural and metabolic retinal markers in patients
with DR in particular as given by the evolving research
at the Department of Ophthalmology at Odense University
Hospital, Denmark.
2. The Retinal Vasculature
The theory of the principle of minimum work in the human
circulatory system was presented by Cecil D. Murray in
1926 [5]. He hypothesized that blood vessels have an optimal
vascular structure, which ensures suﬃcient blood ﬂow with
the least possible energy. This optimal geometry is perfectly
adapted for the metabolic need. Deviations from an optimal
vasculature will cause less eﬃcient circulation and interrupt
the metabolic capacity. This is in particular evident in
diabetes which is known to be associated with changes in
the optimal retinal vascular architecture [6].
Semiautomatic software has enabled in vivo, noninvasive
evaluation of the geometrical features of the retinal vascular
tree, hence providing valuable information about the condi-
tion of the systemic microvascular network and the impact
of diabetes.
3. Retinal Vascular Fractal Dimension
Retinal vascular fractal analysis quantiﬁes the fractal pattern
of the retinal vascular tree [7]. Fractal patterns are a common
phenomenon in nature and are seen in branching structures
as frost crystals, treebranches, and lightning. Fractal structures
are characterized by a self-similar pattern that is unaﬀected
by diﬀerence in size. That is, under a diﬀerent magniﬁcation,
a smaller part of the whole will have the same structure as
the bigger part. Retinal vascular fractal analysis is a validated
method to describe the density and complexity of the retinal
vascular tree in one parameter: the retinal vascular fractal
dimension (Fd) [8]. Fd is deﬁned as a noninteger unit between
1 and 2 (i.e., 1.4263), which increases correspondingly to
the density of the retinal vascular tree.
Semiautomated computer software like SIVA-Fractal
(Singapore Institute Vessel Assessment-Fractal, School of
Computing, National University of Singapore, Singapore)
can be used to calculate Fd. Disc-centered color fundus
photos are analyzed by a standardized protocol. The optic
disc is automatically detected, and a grid is used to identify
a zone between 0.5 and 2.0 disc diameters from the disc
margin (Figure 1). All vessels that pass through the deﬁned
zone are automatically traced by the software which provides
a skeletonized pattern of traced vessels. Any artefacts or
misidentiﬁed vessels are manually removed by comparison
to the original color fundus photo. Fd is then calculated by
the software from the reﬁned line tracing with the box-
counting method. This is a well-deﬁned method with a high
intragrader reproducibility [8].
Previous studies have correlated lower retinal Fd with
ischemic stroke, hypertension, and chronic kidney disease.
In patients with diabetes, Fd has been correlated to vascular
parameters such as retinal vessel calibers, blood ﬂow,
presence and progression of DR, and the development of
proliferative diabetic retinopathy (PDR) [6, 9–14].
4. Retinal Vessel Caliber and Advanced
Geometrical Measurements
Retinal vessel caliber can also be measured noninvasively
[15, 16]. Several studies found a correlation between retinal
vessel calibers and micro- and macrovascular complications
(a) (b)
Figure 1: Cropped retinal image (a) and the corresponding skeletonized image (b) where all vessels are traced. Processed by fractal analyzer.
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in patients with diabetes [17–21]. Cross-sectional studies
have associated wider retinal venular diameters with the
presence of DR [6], and narrower arteriolar calibers have
been correlated with more severe DR [22–25]. Prospective
studies have also conﬁrmed associations between wider
venular calibers, progression of DR, and incident prolifera-
tive DR [26, 27]. In addition, two studies found wider
arteriolar calibers as predictors for incident DR [28, 29].
Semiautomated computer software (IVAN, Department
of Ophthalmology and Visual Science, University of
Wisconsin, Madison, WI, USA) can be used to measure
retinal vessel calibers in optic disc-centered color fundus
photos. The optic disc is automatically detected, and a grid
placed on top identiﬁes a zone between 0.5 and 1.0 disc
diameters from the disc margin. Vessels that course through
this zone are automatically traced and marked as arterioles
(red) or venules (blue) and manually adjusted for any
inaccuracies in grid placement or tracing. Central retinal
arteriolar and venular equivalents (CRAE and CRVE) are
then calculated using the Big-6 formula. The method com-
bines the diameter measures of the six largest arterioles
and venules to estimate the diameter of the central retinal
artery and vein which is then expressed as CRAE and
CRVE, respectively [16, 30] (Figure 4(a)).
In recent updates,measurements of retinal vessel diameter
have been integrated in SIVA, where they can be performed in
addition to measurements of advanced retinal vascular
parameters like tortuosity (Figure 2), branching coeﬃcient,
and length-diameter ratio of the retinal vessels [19, 31, 32].
5. Retinal Oximetry
Retinal oxygen metabolism has a key role in ischemic retinal
diseases like DR [33–35]. The retinal oxygen saturation can
be measured noninvasively in the larger retinal vessels by
retinal oximetry based on dual-wavelength fundus photog-
raphy [36]. In retinal oximetry, the oxygen saturation is
measured by the color of hemoglobin given that oxygenated
and deoxygenated hemoglobin has diﬀerent colors. Retinal
images of the same area are captured at a wavelength sensi-
tive (nonisosbestic) and insensitive (isosbestic) to changes
in absorptivity between oxygenated and deoxygenated hemo-
globin. The oximeter calculates the optical density of retinal
vessels at both wavelengths. The ratio of the two densities is
then approximately linearly related to the hemoglobin oxy-
gen saturation which can then be given numerically or as a
color saturation map (Figure 3) [37, 38].
Clinical studies in DR have consistently demonstrated
higher retinal venous oxygen saturation in patients with
DR [39–43]. At ﬁrst, this may conﬂict the traditional concept
of DR as an ischemic disease. However, the observation may
be explained by (1) poor oxygen distribution to the tissue,
(2) compensatory increased oxygen supply, or (3) less oxygen
consumption in the retinal tissue [37]. In particular, it has
been speculated that patients may have a poor oxygen distri-
bution to the ischemic retinal tissue as given by capillary
nonperfusion, arteriovenular shunting, thickening of the
capillary walls, and greater aﬃnity for oxygen in glycosylated
hemoglobin [33, 37].
6. Fyn County Eye Study
This was a population-based cohort of patients with type 1
diabetes in Fyn County, Denmark, identiﬁed in 1973 by
insulin prescriptions [44, 45]. Seven hundred twenty-seven
patients were identiﬁed, and it was estimated that the patient
material was more than 98% complete [44].
By March 2007, 320 patients were still alive and resident
in Denmark. Of these, 208 (65.0%) agreed to participate in a
clinical study [46, 47] aimed to correlate retinal noninvasive
structural markers to long-term micro- and macrovascular
complications. Median age and duration of diabetes were
58.7 and 43 years, respectively, and 60.0% were men.
Nine mydriatic 45° color fundus ﬁelds were captured
by Topcon TRC-NW6S (Topcon, Tokyo, Japan) and
graded for DR according to the Early Treatment Diabetic
Retinopathy Study (ETDRS) Group adaptation of the
modiﬁed Airlie House classiﬁcation of DR [48, 49]. IVAN
was used to grade for retinal calibers [50], and the retinal
vascular fractal dimension was graded by the International
Retinal Imaging Software (IRIS-Fractal), which was the
standard of the time [51].
Prevalences of long-term complications were 43% for
PDR and 53%, 33%, and 22% for diabetic neuropathy,
nephropathy, and macrovasculopathy, respectively [52]. In
a multiple logistic regression model, a lower CRAE correlated
independently with diabetic nephropathy (odds ratio (OR)
2.17 per standard deviation (SD) decrease in CRAE) and
macrovascular disease (OR 3.17 per SD decrease in CRAE),
but not with PDR or diabetic neuropathy [17]. CRVE was
unrelated to all complications.
Interestingly, a diﬀerent signal was found in retinal
vascular fractal analysis. In a multiple logistic regression
model, a lower retinal vascular fractal dimension correlated
Zone A
Zone B
Zone C
Figure 2: Retinal image processed by SIVA and used for analysis of
vascular caliber, fractal dimension, tortuosity, length-diameter ratio,
and branching coeﬃcients. Marked are zone A, zone B, and zone C,
located 0–0.5, 0.5–1.0, and 0.5–2.0 disc diameters from the center of
the disc. In zones B and C, retinal arterioles have been marked in red
and venules in blue.
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independently with PDR (OR 1.57 per SD decrease in
Fd) and diabetic neuropathy (OR 1.42 per SD decrease
in Fd), but not with diabetic nephropathy or macrovascular
disease [53].
In conclusion, the study demonstrated that in long-term
surviving type 1 diabetic patients, noninvasive retinalmarkers
associate with intra- as well as extraocular micro- and
macrovascular complications.
7. The Danish Cohort of Pediatric Diabetes
1987 (DCPD1987)
The DCPD1987 was initially a population-based study of
children with type 1 diabetes. Approximately 75% (n=720)
of all Danish type 1 diabetic children aged 18 and below
participated in 1987 [54–56]. At the time of the ﬁrst eye
examination in 1995, the cohort had been reduced to 339
participants [54]. Surprisingly, poor glycemic control was
found at every stage of the study, and in 1995, many patients
showed early signs of complications with some degree of DR
in 60% [54, 57, 58].
In 2011, a long-term follow-up was initiated with several
purposes. On one hand, the incidence and progression of
microvascular complications and mortality was of interest
[59, 60]. On the other hand, the study aimed to identify early
retinal markers for diabetic retinopathy, nephropathy, and
neuropathy. Semiautomated computer software had in the
recent years made it possible to reliably measure various
parameters in the retinal vascular tree. In total, 185 partici-
pants were included. The vessel analyses were performed
on retinal images from the study in 1995 and linked to
microvasculopathy in 2011. In multiple regression analyses,
a consistent relation between narrower retinal arteriolar
calibers (OR 2.96, 2.63, and 1.56 per 10μm decrease), wider
retinal venular calibers (OR 1.52, 1.76, and 1.36 per 10μm
increase), and lower fractal dimensions (OR 1.17, 1.40, and
1.22 per 0.01 decrease in fractal dimension) and the 16-year
incidences of diabetic neuropathy, nephropathy, and pro-
liferative retinopathy were found [61–63]. These ﬁndings
could possibly be indications of a shared pathogenic pathway
for microvasculopathy in diabetes mellitus.
This study has been the longest prospective study to date
of both retinal vessel calibers and retinal fractal dimensions
and their predictive value on diabetic microvascular compli-
cations. In addition, the study also demonstrated cross-
sectional associations between increased retinal vascular
branching coeﬃcients (BC) and diabetic nephropathy (OR
3.10 for patients with increased arteriolar BC) and diabetic
neuropathy (OR 2.11 for patients with increased venular
BC) [64].
8. Retinal Vascular Calibers in Diabetic Macular
Edema (DME)
The aim of this study [65] was to evaluate global and macular
retinal vessel caliber changes after focal/grid laser treatment
for DME in order to provide physicians with a potential tool
to monitor the progress and success of DME treatment.
We included retrospectively 69 eyes from 46 patients
from a photographic screening clinic. Patients had clini-
cally signiﬁcant macular edema according to the ETDRS
criteria [66] and had been treated with focal/grid laser
photocoagulation according to the modiﬁed ETDRS protocol
[66–68]. Furthermore, retinal photos (disc- and macula-
centered) should be available from within 6 months prior
to laser photocoagulation and 2–12 months after.
Computer-assisted measurements of the retinal vessels
were performed by two methods: the standard IVANmethod
(69 eyes, 31 controls), which was used to assess the retinal
vessels “globally” surrounding the optic disc margin, and a
modiﬁed method m-IVAN (Figure 4) (68 eyes, 31 controls)
which was used to measure macular vessels. Measurements
were denoted as macular retinal arteriolar and venular
equivalent (MRAE and MRVE, resp.). The modiﬁed method
had a high concordance correlation coeﬃcient (0.95 for
arterioles and 0.99 for venules).
Median age was 60 years (range 29–79 years), and the
overall duration of diabetes was 13 years (range 1–41 years).
By the standard IVAN method, we found no signiﬁcant
diﬀerence in retinal vessel diameter before or after the
treatment, neither in patients with DME or in untreated
control eyes (Table 1).
By the m-IVAN method, we found a statistically sig-
niﬁcant decrease in vessel diameters in macular arterioles
and venules after laser treatment (MRAE 73.5μm versus
72.0μm, p = 0 04, and MRVE 63.5μm versus 62.4μm,
100%
75%
50%
25%
0%
(a) (b)
Figure 3: (a) Retinal image processed by Oxymap. (b) Vessels colored in accordance with the level of oxygen in the vessel.
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p = 0 02, resp.). In contrast, the modiﬁed analysis of the 32
untreated fellow eyes, serving as controls, showed no signiﬁ-
cant change in either arteriolar or venular diameter after laser
treatment. There was no association between the type of
edema (focal, n=36, or diﬀuse, n=31) and vascular caliber
changes after laser treatment (data not shown).
The narrowing of the macular arterioles and venules
may reﬂect the autoregulatory reduced blood ﬂow caused
by partial destruction of retinal tissue in accordance with
the oxygen theory suggested by Stefansson et al. [35].
9. Noninvasive Retinal Markers of Treatment
Outcome in PDR
“The individually-marked panretinal laser photocoagula-
tion for proliferative diabetic retinopathy study” (IMPETUS
2018) has been designed to identify the threshold level of
progression of PDR after panretinal photocoagulation
(PRP). In particular, the study addresses noninvasive struc-
tural and metabolic markers of treatment outcome in order
to archive suﬃcient treatment but avoid side eﬀects like
visual ﬁeld loss, night blindness, and DME as caused by
excessive PRP.
This is an ongoing 6-month prospective study with
a cohort of treatment-naïve patients with PDR referred
for PRP treatment at the Department of Ophthalmology,
Odense University Hospital. We performed an interven-
tional study with PRP as delivered by a navigated laser
system (NAVILAS®, OD-OS GmbH, Berlin, Germany).
Wide-ﬁeld ﬂuorescein angiography (Optomap, Optos PLC.,
Dunfermline, Scotland, UK), optical coherence tomography
(OCT) and fundus imaging (3D OCT-2000 Spectral Domain
Table 1: Measurements of global and macular retinal vascular diameter.
Method Measurement
Vascular diameter before
laser treatment (μm)± SD
Vascular diameter after
laser treatment (μm)± SD P value
IVAN
CRAE 140.3± 13.2 139.3± 13.1 0.44
CRVE 214.1± 23.6 213.1± 22.8 0.40
Control CRAE 141.5± 14 138.6± 15.8 0.26
Control CRVE 213.1± 24.2 214.0± 25.0 0.84
Modiﬁed IVAN
Macular arterioles 73.5± 11.2 72.0± 10.7 0.04∗
Macular venules 63.5± 17.8 62.4± 17.6 0.02∗
Control macular arterioles 71.7± 11.9 71.8± 12.2 0.89
Control macular venules 62.0± 15.5 61.2± 15.7 0.10
Data are presented as mean with standard deviation (SD). Vessel diameters are compared before and after laser treatment with the Wilcoxon signed-rank test.
∗Statistically signiﬁcant. CRAE: central retinal arteriolar equivalent; CRVE: central retinal venular equivalent; m-IVAN: modiﬁed IVAN; MRAE: macular
retinal arteriolar equivalent; MRVE: macular retinal venular equivalent [65].
Zone A Foveal zone A
(a) (b)
Figure 4: Retinal images processed by IVAN and used for vascular caliber analysis. Images are divided into zone A and zone B located 0–0.5
and 0.5–1.0 disc diameters from the center. Arterioles are marked in red and venules in blue. (a) Regular IVAN, centered at the optic disc.
(b) Modiﬁed IVAN, centered at the fovea.
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OCT, Topcon, Tokyo, Japan), and retinal oximetry (Oxymap
model T1; Oxymap, Reykjavik, Iceland) were performed at
baseline and three and six months after PRP. IVAN and
SIVA were used to measure retinal vascular calibers, fractal
dimension, tortuosity, length-diameter ratio, and branching
coeﬃcients. At months 3 and 6, wide-ﬁeld ﬂuorescein
angiography was used to evaluate PDR activity and patients
were dichotomized according to progression or nonprogres-
sion of PDR.
We included 65 eyes in this study. Median age and
duration of diabetes were 53.2 and 20 years, respectively,
and 67% were male. At present, all clinical examinations have
been concluded and the initial results have been reported.
At baseline, patients in the two groups did not diﬀer
according to age, duration of diabetes, HbA1c, blood pres-
sure, total laser energy delivered, retinal oxygen saturation,
or retinal vascular calibers. However, eyes with progression
of PDR at month 3 developed a higher retinal venular oxygen
saturation than those in patients without progression (+4.1%
versus −1.8%, p = 0 02) [69]. In a multiple logistic regression
analysis, each 1.0%-point increment in retinal venular
oxygen saturation independently associated with a 30%
higher risk of PDR progression at month 3 (p = 0 02) but
not at month 6. These data align with prior studies that
associate advanced DR with a higher retinal venular
oxygen saturation [33]. We demonstrated that a postlaser
decrement in retinal venular oxygen saturation indicates
a favorable treatment outcome. Hence, we conclude that
retinal oximetry may serve as a breaking-the-wave indicator
of successful PRP.
Interestingly, the retinal calibers also correlated with
treatment outcome. From baseline to month 3, the retinal
arteriolar calibers decreased by 5.9μm (p < 0 01) in patients
with progression of PDR, and likewise, the retinal venular
calibers decreased by 4.7μm (p = 0 03) in patients with
nonprogression of PDR [70]. These data support the ﬁndings
from DCPD1987 [63] and others [71] which indicate that
lower retinal arteriolar calibers and higher retinal venular
calibers link to microvascular dysfunction in DR. Like in
retinal vascular oxygen saturation measurements, this is
likely to be a direct marker of treatment outcome after PRP.
10. Noninvasive Retinal Markers of Treatment
Outcome in DME
It was established by the ETDRS that focal/grid laser pho-
tocoagulation reduces the risk of visual loss in patients
with DME but with a small likelihood of visual improve-
ment [72]. In recent years, intravitreal inhibitory vascular
endothelial growth factor (VEGF) agents like bevacizumab
[73], ranibizumab [74], and aﬂibercept [75] have consistently
demonstrated eﬃcacy and visual improvement in DME
treatment. However, a high number of injections are needed
to achieve sustainable visual improvement, and the burden
of intravitreal injections is a substantial concern for both
patients and health care systems.
Modern navigated retinal photocoagulation enables clini-
cians to preplan and deliver planned spots in an automatic
mode as adjunctive therapy to intravitreal anti-VEGF. This
led to the observation of a reduced need for intravitreal
injections of bevacizumab [76] and ranibizumab [77] with a
similar improvement in best-corrected visual acuity (BCVA).
The “aﬂibercept and navigated versus conventional laser
in diabetic macular edema study” (ADDENDUM) is an
ongoing, randomized 12-month prospective 1 : 1 study of
patients with DME that aims to examine the treatment
response of intravitreal aﬂibercept and navigated retinal pho-
tocoagulation (NAVILAS OD-OS GmbH, Teltow, Germany)
as compared to intravitreal aﬂibercept and conventional
retinal photocoagulation (PASCAL Photocoagulator, Opti-
Medica, Santa Clara, California) [78]. Based on previous
work, we aim to include a minimum of 48 diabetic patients
with clinical signiﬁcant macular edema from the Region of
Southern Denmark. Patients are randomized at baseline
and receive a loading dose of three monthly intravitreal
injections of aﬂibercept followed by central retinal photoco-
agulation at month 3. From month 4, patients are followed
monthly and additional injections are given pro re nata.
In addition, we wish to identify noninvasive retinal
markers for successful treatment outcome, and we hypothe-
size that treatment leads to lower retinal vascular diameters,
lower retinal fractal dimensions, and higher retinal oxygen
saturation in patients with a successful treatment outcome.
11. Conclusion
Diabetic retinopathy may lead to sight-threatening end-stage
complications like DME or PDR, but so far, it has been
diﬃcult to predict patients at high risk of progression. Like-
wise, it is diﬃcult to individualize treatment, and patients
are often treated in a one-size-ﬁts-all approach.
Retinal markers of structure and metabolism oﬀer
detailed and noninvasive information of the retinal vascula-
ture. In our research group, we have strived to advance this
ﬁeld of research from bench to bedside. Firstly, we have
demonstrated cross-sectional association between retinal
calibers and fractal dimension with diabetic micro- and
macrovascular complications [17, 53]. Secondly, we have
established predictive values of these structural makers of
long-term complications in a 16-year prospective study
[61, 63] and of macular changes in patients treated for
DME [65]. Finally, we have demonstrated that changes
in retinal oxygen saturation and retinal vascular calibers
diﬀer according to treatment outcome in patients with
PDR [69, 70], and we have a similar ongoing study in
DME [78].
Diabetes has become a global epidemic. This causes
an increasing burden on the health care society. Screening
for DR has often been oﬀered annually for most patients,
but ﬂexible, individualized screening intervals may reduce
the number of unnecessary screening episodes for most
patients [79, 80]. Given that glycemic dysregulation only
explains a small proportion of the risk or DR-progression
[4], additional risk markers are important. We have demon-
strated that retinal arteriolar narrowing, venular dilation, and
decrement in fractal dimension all independently predict
long-term development of diabetic nephropathy, diabetic
neuropathy, and PDR [61, 63]. A potential use of this could
6 Journal of Diabetes Research
be automated software combining these measurements
with grading of vascular DR lesions which may lead to
individualized risk stratiﬁcation outcomes.
There is a substantial phenotype diﬀerence in patients
treated for DME and PDR. With that in mind, individualized
treatment is a tempting approach, but so far, it has been dif-
ﬁcult to make early posttreatment stratiﬁcation according to
treatment response. We have addressed this issue in prospec-
tive clinical trials in DME and PDR [69, 70, 78], and so far,
we have demonstrated that successful treatment outcome
after panretinal photocoagulation (PRP) in PDR is associated
with a lower postlaser retinal oxygen saturation. On the other
hand, patients with an increasing retinal venous oxygen sat-
uration of at least 3.0% three months after PRP had a 4.0
times increased risk of progression in PDR [69]. Others have
demonstrated that increasing levels of DR associate with
higher retinal venous oxygen saturation [39], and, thus, it is
plausible that successful treatment is able to break this dys-
functional pattern, presumably by lowering the intravascular
oxygen saturation and increasing the metabolic supply to the
retinal tissue.
It is a general limitation of the abovementioned studies
that the structural and metabolic state of the retinal vascula-
ture may ﬂuctuate during many years of disease in reﬂection
to the development of DR. This can be diﬃcult to assess on
an individualized level with only a few points of measure-
ment captured during the years. In addition, the study on ret-
inal vascular calibers in diabetic macular edema was limited
by a relatively low number of patients, and the study was
not adjusted for blood pressure, which may have confounded
the results.
Diabetic retinopathy is a complex retinal disease inﬂu-
enced by several local and systemic factors. Noninvasive
markers like retinal vascular calibers, fractals, and oxygen
saturation oﬀer additional information about the morphol-
ogy and function of the retina. Likewise, novel potential
biomarkers like OCT angiography may provide valuable
information if cross-sectional associations with diabetes
[81] and DR [82] can be conﬁrmed in prospective studies.
Repeatedly individualized measurements oﬀer valuable
information regarding the risk of progression and response
to treatment. Upcoming studies should pursue this issue even
further to make this an integrated part of the clinical risk
assessment at our and other departments treating patients
with DR.
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